Full Answer
How many times has Moderna stock split in its history?
Moderna (MRNA) has 1 split in our Moderna stock split history database. The split for MRNA took place on July 22, 2010. This was a 1 for 4 reverse split, meaning for each 4 shares of MRNA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
Will Moderna stock price go up or fall?
The Moderna stock price is 271.850 USD today. Will Moderna stock price grow / rise / go up? Yes. The MRNA stock price can go up from 271.850 USD to 379.147 USD in one year. Is it profitable to invest in Moderna stock? Yes. The long-term earning potential is + 39.47 % in one year. Will MRNA stock price fall / drop? No. See above .
Why did Moderna's stock go up 30%?
New York (CNN Business) Moderna's stock price skyrocketed as much as 30% on Monday after the biotech company announced promising early results for its coronavirus vaccine. As ordinary investors piled in, two insiders were quietly heading for the exits.
What is Moderna's (multi) stock price potential for next year?
Their forecasts range from $85.00 to $395.00. On average, they anticipate Moderna's stock price to reach $242.88 in the next year. This suggests a possible upside of 47.1% from the stock's current price.
What does "hold" mean in Moderna?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares. View analyst ratings for Moderna or view top-rated stocks.
Is Moderna a hold?
Wall Street analysts have given Moderna a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Moderna wasn't one of them.
When will Moderna be available to the public?
If future studies go well, Moderna has said its vaccine could be available to the public as early as January. Charles Elson, a corporate governance expert at the University of Delaware, said the Moderna stock sales underscore why he has always believed executives should not sell stock while they are at the company.
How much did Lorence Kim sell Moderna?
Lorence Kim, Moderna's chief financial officer, exercised 241,000 options for $3 million on Monday, filings show. He then immediately sold them for $19.8 million, creating a profit of $16.8 million. In quest for vaccine, US makes 'big bet' on company with unproven technology.
A sell-off in growth stocks and a setback for a vaccine mandate pushed the stock lower
Fool since 2011. I write about consumer goods, the big picture, and whatever else piques my interest. Follow me on Twitter to see my latest articles, and for commentary on hot topics in retail and the broad market. Follow @tmfbowman
What happened
Shares of Moderna ( NASDAQ:MRNA) were falling in January as the biotech stock was affected by the broad sell-off in growth stocks, and as investors seemed to fear that the company's tailwinds from its COVID vaccine may have peaked.
So what
Moderna dropped sharply over the first three sessions of the month, falling 15% with a broader sell-off in growth stocks as investors reacted to expectations of rising interest rates, which make growth stocks less attractive.
Now what
With the stock down more than two-thirds from its peak in September, this could be a good buying opportunity for Moderna stock. The company has a number of different vaccine trials in the works on diseases, ranging from HIV to Zika to cancer.
Is the coronavirus vaccine tailwind over?
According to the U.S. Centers for Disease Control and Prevention (CDC), as of July 21, 161.9 million people in the U.S. have been fully vaccinated against COVID-19. Many more have received vaccines elsewhere in the world.
What else does Moderna have to offer?
Beyond COVID-19, Moderna's mRNA vaccine platform shows huge potential. The company's pipeline currently boasts more than a dozen programs, most of which are potential vaccines against various infectious illnesses. In early July, the biotech started a phase 1/2 clinical trial for mRNA-1010, an investigational flu vaccine.
Not too late to get in
There are two important reasons why it's not too late to buy shares of Moderna. First, the company will continue to benefit from its COVID-19 vaccine. Second, the biotech's long-term thesis (supported by the success of mRNA-1273) is attractive.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
